Patients

Being treated in a Comprehensive Cancer Center

Find out more about us

Healthcare professionals

Research and UNICANCER patient management

Your page

Find a Center

Retrouvez les Centres de lutte contre le cancer sur l'ensemble du territoire

R&D UNICANCER

R&D UNICANCER develops clinical and translational research that is both pertinent and rigorous, with the aim of improving cancer treatments and patient management.

 

Created in 1994, R&D UNICANCER (formerly the Clinical and Therapeutic Research Bureau – BECT) is an academic sponsor and operator of clinical trials in cancer research. It works directly with the clinical research units  at the 20 French Comprehensive Cancer Centers R&D UNICANCER is also partially or wholly responsible for drug safety monitoring and regulatory affairs for the trials promoted by the UNICANCER Group making such a request.

 

R&D UNICANCER’s goal is to develop clinical and translational research that is both pertinent and rigorous in the aim of improving cancer treatments and patient management.

R&D UNICANCER has received the clinical investigation Center certification from the French Ministry of Health and INSERM. As such, it is eligible for teaching, research, reference and innovation missions (MERRI), the funding method for research specific to hospital Centers.

Focusing on areas insufficiently covered by the pharmaceutical industry

Clinical research is carried out on humans and must obey a protocol. It aims to enrich our knowledge about a drug, disease, procedure or care protocol.
R&D UNICANCER’s research strategy focuses on areas insufficiently covered by the pharmaceutical industry.

This strategy is reinforced by an exclusive financial partnership with the Ligue nationale contre le cancer (anti-cancer League).

Accelerating therapeutic innovations with translational research

Translational research is one of the priority orientations in development at R&D UNICANCER. It is laboratory research that allows for rapidly transposing innovative techniques to patient care.

All clinical research promoted R&D UNICANCER include the collection of tumours and/or blood samples for implementing translational research programmes.

 

 

Developing cooperation to advance research

R&D UNICANCER cooperates with key players in cancer research: learned societies, patient associations, the pharmaceutical industry, and public institutions. Though it originates from French Comprehensive Care Centers, R&D UNICANCER promotes studies in over 160 French and foreign Centers. Its international influence is recognised by the European Organisation for Research and Treatment of Cancer (EORTC) and R&D UNICANCER hosts the French Liaison Office whose goal is to accelerate and facilitate trials and promoting the EORTC in France.

EORTC Liaison Office

 

R&D UNICANCER documents

 

couverture RA 2015 R&D UNICANCERR&D UNICANCER 2016 annual report

Read animated PDF

Download PDF(4 Mo)

Previous reports

 

 

 

 

R&D UNICANCER presentation leaflet

Download PDF

Two-pagers on UNICANCER expert groups

Download the Real World Data Group two-pager

Download the Immno-Oncology Group two-pager

Download the UNITRAD two-pager